imuvert and Neoplasms

imuvert has been researched along with Neoplasms* in 2 studies

Trials

1 trial(s) available for imuvert and Neoplasms

ArticleYear
Phase I trial of ImuVert (natural membrane vesicles associated with ribosomes) in patients with advanced cancer.
    Cancer immunology, immunotherapy : CII, 1992, Volume: 35, Issue:5

    ImuVert, a new biological response modifier, was evaluated for toxicity and potential efficacy in patients with advanced cancer. This agent consists of sized, labile, natural membrane vesicles associated with ribosomes derived from Serratia marcescens. ImuVert induces enhanced in vitro macrophage and natural-killer-cell-mediated cytotoxicity, and has demonstrated antitumor activity in palpable animal tumor systems. A group of 39 patients with a variety of tumors, 25 men, 14 women, with a mean performance status (Karnofsky) of 80% and median age of 57 years were entered into this trial. ImuVert was administered subcutaneously weekly for a minimum of 3 weeks. A total of 183 treatments were evaluated. Flu-like systemic toxicities, including fever, chills, nausea, vomiting, diarrhea and hypotension were observed. Erythema, induration and tenderness developed at the injection sites. Myelosuppression, thrombocytopenia, anaphylaxis, rental and hepatic toxicities did not occur. All symptoms resolved within 24 h. Two patients with nodular lymphoma achieved a partial response and two minor responses were seen in patients with glioblastoma and melanoma. On the basis of ImuVert's biological activity, and tolerable toxicity it warrants further clinical investigation.

    Topics: Adult; Aged; Antineoplastic Agents; Biological Products; Female; Humans; Immunologic Factors; Killer Cells, Natural; Leukocyte Count; Male; Middle Aged; Neoplasms; Serratia marcescens

1992

Other Studies

1 other study(ies) available for imuvert and Neoplasms

ArticleYear
Effect of prior cancer chemotherapy on human tumor-specific cytotoxicity in vitro in response to immunopotentiating biologic response modifiers.
    Journal of the National Cancer Institute, 1991, Jan-02, Volume: 83, Issue:1

    Tumor-specific cytotoxicity was measured in fresh human biopsy specimens by a modification of the differential staining cytotoxicity assay. ImuVert, a cytokine inducer derived from Serratia marcescens, which produces broad-spectrum activation of both macrophages and lymphocytes, was dramatically more effective when it was tested in tumors obtained from patients with previously treated, chemotherapy-responsive adenocarcinomas (breast and ovary) than when it was tested in tumors obtained from either previously untreated patients or previously treated patients with chemotherapy-refractory adenocarcinomas (colon, lung, pancreas, stomach, kidney, gallbladder, uterus, and prostate). Similar findings, relating to prior chemotherapy treatment status, were obtained for tumor necrosis factor and interferon gamma, but not for interleukin-2 or interferon alpha. On the basis of these findings and on other evidence in the literature, we speculate that response to chemotherapy produces massive release and processing of tumor antigens. We further speculate that this response leads to a state in which the human immune system is primed (via in situ vaccination) to respond to exogenous macrophage-activation signals with potent, specific antitumor effects.

    Topics: Adenocarcinoma; Antineoplastic Agents; Biological Products; Biopsy; Breast Neoplasms; Cell Survival; Colonic Neoplasms; Drug Screening Assays, Antitumor; Female; Humans; Immunologic Factors; Macrophages; Neoplasms; Ovarian Neoplasms; Tumor Cells, Cultured

1991